Penn Medicine launches first clinical trial for uterine transplant in the northeast
(University of Pennsylvania School of Medicine) Penn Medicine will conduct the Northeast's first clinical trial of uterine transplants, to provide women with Uterine Factor Infertility (UFI) -- an irreversible form of female infertility that affects as many as 5 percent of women worldwide and 50,000 women in the United States -- with a new path to parenthood.
Authors: Dolmans MM, Masciangelo R Abstract Improvements in cancer treatments have increased the chances of survival of young cancer patients, but have given rise to other issues, like premature ovarian insufficiency and infertility. Preservation and subsequent restoration of ovarian function in these patients is now possible thanks to ovarian tissue cryopreservation and transplantation. However, safety concerns about the possible presence of cancerous cells in the tissue to be cryopreserved must be addressed. Indeed, reimplantation of malignant cell-contaminated ovarian tissue could potentially lead to recurrence ...
Conditions: Primary Ovarian Insufficiency; Female Infertility Intervention: Procedure: Ovarian tissue transplant Sponsor: University of Pittsburgh Not yet recruiting
Transplantation of the uterus is required in cases of absolute uterine factor infertility (AUFI), which are caused either because of uterus deficiency (congenital or after a hysterectomy) or existence of non-functional uterus.
Uterus transplantation (UTx) has been successfully introduced as a treatment option for women with absolute uterine factor infertility (AUFI). AUFI representing approximately 3% to 5% of the female general population is linked to either congenital uterine agenesis (Mayer-Rokitansky-Küster-Hauser syndrome), major congenital uterine malformation (hypoplastic uterus, fraction of bicornuate/unicornuate uterus), a surgically absent uterus, or an acquired condition (intrauterine adhesions, leiomyoma) linked to uterine malfunction that causes implantation failure or defect placentation. The world’s first clinical uteru...
This study presents a summary of the investigations that indicate the key role of stem cell therapy in regeneration and renovation of defective parts.
Although cancer remains a critical health concern, significant medical advances in cancer detection and treatment have improved survival rates for patients. In children receiving total body radiation (TBI), bone-marrow transplant (BMT), or cyclophosphamide equivalent dose (CED) of>4,000mg/m2, the risk of infertility is significant. The National Physicians Cooperative (NPC) has published site-specific articles compiling data regarding use of cryopreserved tissue, return of endocrine function, and pregnancy outcomes, however no comprehensive review has been conducted.
Reduced intensity conditioning (RIC) is increasingly used for hematopoietic stem cell transplantation (HCT). Risk of infertility and primary gonadal insufficiency secondary to standard myeloablative (MAC) HCT is high, but little is known of these complications following use of RIC HCT.
Fanconi anemia (FA) is a relatively rare genetic condition with primary sequelae of bone marrow failure, hematologic malignancies, and squamous cell cancers (SCC) of head/neck, breast, and anogenital tract. Many patients require hematopoietic stem cell transplant (bone marrow transplant, BMT) to treat marrow dysfunction, but risk of future malignancies remains. Female patients are at risk of reproductive complications, including infertility related to primary ovarian insufficiency (POI) and gynecologic cancers.
This study presents a summary of the investigations that indicate the key role of stem cell therapy in regeneration and renovation of defective parts. PMID: 29571018 [PubMed - as supplied by publisher]
Uterus transplantation (UTx) has become an alternative to gestational surrogacy and adoption for women with uterine factor infertility (UFI). Br ännström et al. achieved the first human delivery after UTx in 2014, and to date a total of 8 babies have been born after UTx from living donors. This outcome has attracted much attention worldwide and many countries are now preparing for UTx.There are an estimated 60,000 women of reproductive age with UFI in Japan and these patients cannot have biological children because gestational surrogacy is forbidden in Japan.